Trump's Generic Drug Tariff Threat: Two Years Is a Long Time

US President Donald Trump has unveiled the final phase of his pharmaceutical tariff strategy, announcing that imported generic medicines will remain duty-free until August 1, 2028, before facing some of the steepest tariffs ever proposed for the sector. 

In a Truth Social post on July 21, 2026, Trump said imported generics would continue to enjoy zero tariffs for two years, after which they would face a 100% tariff for one year and 200% from August 2029, unless manufacturers establish production facilities in the United States.

Trump said the two-year transition period is designed to give pharmaceutical companies enough time to relocate generic drug manufacturing to the US companies that continue to rely on imports after that period would face punitive tariffs.

The latest announcement completes Trump's effort to cover almost every segment of pharmaceutical imports.

• On September 25, 2025, he announced plans for a 100% tariff on imported branded and patented medicines, although that proposal was never implemented and was later replaced. 
• On April 2, 2026, the administration formally announced tariffs of up to 100% on specified branded medicines and key pharmaceutical ingredients under the Section 232 national security framework, while excluding generic medicines. 
• The July 21 announcement now brings generic drugs into the proposed tariff regime, leaving virtually no major pharmaceutical category outside Trump's reshoring strategy.

The US Market

The United States imported $213 billion worth of pharmaceutical products in 2025, including $94.1 billion of finished medicines sold in retail packs—the category that includes generic medicines.

Estimating the value of generic medicine imports is not straightforward because US customs data do not identify generics separately. Instead, they are classified under HS 3004, which also includes patented medicines, branded generics and over-the-counter drugs. As a result, estimates rely on industry data rather than customs statistics.

India Impact  

India has the most at stake among generic drug exporters. It exported $25.8 billion of pharmaceuticals worldwide in 2025, of which $9.7 billion, or 37.7%, went to the US, making America India's largest pharmaceutical export market.

Indian companies supply 47% of all generic prescriptions dispensed in the US, making India the country's largest source of affordable generic medicines. However, because generics are sold at very low prices, India's share of the value of US generic imports is estimated at only 30%, well below its share of prescriptions.

The proposed tariffs could significantly affect India's largest pharmaceutical export market, but the impact is unlikely to be uniform.

Many Indian generic medicines sell for seven to ten times less than branded alternatives. Even after a 100% tariff, many products could remain cheaper than branded medicines, meaning much of the additional cost would likely be passed on to US healthcare providers, insurers and patients rather than immediately eliminating Indian exports.

The greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable.

Several leading Indian drug makers already manufacture in the United States. Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla and Dr. Reddy's Laboratories operate FDA-approved manufacturing facilities there. Cipla is expanding production at plants in Massachusetts and New York, while Dr. Reddy's Laboratories is willing to increase US manufacturing if it makes commercial sense. Sun Pharma, by contrast, has said its existing US manufacturing footprint is sufficient and that it has no immediate expansion plans.

Reshoring Not Easy

Relocating large-scale generic drug production to the United States will be difficult. Generic medicines operate on extremely thin margins and depend on global supply chains, especially for active pharmaceutical ingredients, many of which continue to come from India and China. Building a fully domestic US supply chain would require substantial investment and would almost certainly increase medicine prices.

The proposal also comes with a long implementation timeline. In US politics, two years is a long time, and the policy could still be modified, delayed or overturned by legal or political developments.

For now, however, Trump has sent a clear signal: pharmaceutical companies have two years to decide whether to manufacture generic medicines in America or risk facing exceptionally high tariffs on exports to the US market.

Bigger Challenge

India's pharmaceutical industry should prepare for a bigger strategic risk than U.S. tariffs: dependence on China.

About 70% of the chemical-based active pharmaceutical ingredients used by Indian drugmakers and nearly 90% of biologic inputs come from China. Yet until the 1990s, India was a leading API producer.

If Beijing were to restrict API exports while expanding sales of higher-value finished medicines, India's drug industry could face serious supply disruptions.

India should therefore make rebuilding its API manufacturing base a national priority by expanding domestic production and reducing reliance on a single supplier.

At the same time, Indian pharmaceutical companies should reduce their dependence on the US market by expanding exports to Europe, Latin America, Africa and Asia.

India's Pharmaceutical Exports by Destination (2025)

($ million)

Rank	Destination	Exports
–	World	25,829.2
1	United States	9,744.6
2	EU-27	4,053.0
3	United Kingdom	783.6
4	South Africa	675.9
5	Nigeria	636.6
6	Brazil	596.7
7	Canada	544.0
8	Australia	475.2
9	Russian Federation	467.3
10	Philippines	408.5
11	Kenya	405.2